Skip to main content

Table 5 Association between VDR polymorphisms and nevus number

From: Serum 25-hydroxyvitamin D3 levels and vitamin D receptor variants in melanoma patients from the Mediterranean area of Barcelona

 

SNP

Position*

Change

MAF%

HWEP^

Genotype

Cases <50(%)

Cases >100(%)

OR (95%CI)a

P additive a

OR (95%CI)b

P additive b

1

rs7136534

48294626

C/T

0.18

0.400

C/C

101 (68.7)

70 (65.4)

1.00

   
      

T/C

40 (27.2)

33 (30.8)

1.15 (0.65- 2.02)

   
      

T/T

6 (4.1)

4 (3.7)

0.78 (0.21- 2.94)

   
      

additive

  

1.03 (0.65- 1.62)

0.903

1.18 (0.73- 1.92)

0.504

2

rs11574027

48287373

G/T

0.10

1.000

G/G

119 (82.1%)

86 (78.9%)

1.00

   
      

T/G

25 (17.2%)

23 (21.1%)

1.35 (0.71-2.57)

   
      

T/T

1 (0.7%)

0 (0%)

NA

   
      

additive

  

1.19 (0.64- 2.21)

0.580

1.30 (0.67- 2.52)

0.431

3

rs11168287

48285414

G/A

0.44

0.869

G/G

43 (29.3)

36 (33.0)

1.00

   
      

A/G

72 (49.0)

57 (52.3)

0.99 (0.55- 1.76)

   
      

A/A

32 (21.8)

16 (14.7)

0.58 (0.27- 1.24)

   
      

additive

  

0.79 (0.55- 1.14)

0.212

0.83 (0.56- 1.23)

0.352

4

rs2238136

48277713

G/A

0.24

0.349

G/G

86 (60.1)

52 (52.5)

1.00

   
      

A/G

47 (32.9)

44 (44.4)

1.61 (0.93- 2.79)

   
      

A/A

10 (7.0)

3 (3.0)

0.47 (0.12- 1.82)

   
      

additive

  

1.11 (0.72- 1.72)

0.636

1.05 (0.66- 1.67)

0.845

5

rs3782905

48266167

C/G

0.36

0.483

C/C

52 (35.9)

42 (38.5)

1.00

   
      

C/G

74 (51.0)

63 (57.8)

1.07 (0.62- 1.83)

   
      

G/G

19 (13.1)

4 (3.7)

0.22 (0.07- 0.71)

   
      

additive

  

0.70 (0.46- 1.06)

0.134

0.69 (0.44- 1.08)

0.099

6

rs2189480

48263828

G/T

0.35

0.238

G/G **

  

0.21 (0.07- 0.66)

   
      

G/G

65 (45.5)

30 (28.6)

1.00

   
      

T/G

68 (47.6)

63 (60.0)

1.92 (1.09- 3.39)

   
      

T/T

10 (7.0)

12 (11.4)

2.97 (1.12- 7.87)

   
      

additive

  

1.80 (1.17- 2.76)

0.006

1.66 (1.05- 2.60)

0.027

7

rs2239179

48257766

A/G

0.44

0.192

A/A

35 (23.5)

36 (33.3)

1.00

   
      

A/G

83 (55.7)

58 (53.7)

0.70 (0.39- 1.26)

   
      

G/G

31 (20.8)

14 (13.0)

0.44 (0.20- 0.99)

   
      

additive

  

0.67 (0.46- 0.99)

0.044

0.67 (0.44- 1.02)

0.060

8

rs11574077

48252927

T/C

0.05

0.463

T/T

129(87.8)

104 (93.7)

1.00

   
      

T/C

17 (11.6)

7 (6.3)

0.54 (0.21- 1.38)

   
      

C/C

1 (0.7)

0 (0.0)

NA

   
      

additive

  

0.52 (0.21- 1.27)

0.135

0.45 (0.17- 1.18)

0.088

9

rs11168267

48251542

C/T

0.07

1.000

C/C

128(85.9)

98 (88.3)

1.00

   
      

T/C

21 (14.1)

12 (10.8)

0.68 (0.32- 1.48)

   
      

T/T

0 (0.0)

1 (0.9)

NA

   
      

additive

  

0.84 (0.41- 1.72)

0.626

0.84 (0.38- 1.84)

0.656

10

rs7975128

48245828

G/A

0.33

0.385

G/G

56 (38.6)

63 (58.9)

1.00

   
      

A/G

64 (44.1)

35 (32.7)

0.47 (0.27- 0.82)

   
      

A/A

25 (17.2)

9 (8.4)

0.29 (0.12- 0.69)

   
      

additive

  

0.51 (0.35- 0.76)

0.0005

0.58 (0.38- 0.87)

0.007

  1. MAF minor allele frequency.
  2. *SNP position from NCBI; ^ HWE Hardy –Weinberg Equilibrium for cases with low number of nevi (cases <50) as reference group; a = adjusted for age and gender; b = adjusted for age. gender and number of melanoma.
  3. ** recessive model for SNP rs3782905.